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Abstract
The cardiac late Na  current is generated by a small fraction of
voltage-dependent Na  channels that undergo a conformational change to a
burst-gating mode, with repeated openings and closures during the action
potential (AP) plateau. Its magnitude can be augmented by
inactivation-defective mutations, myocardial ischemia, or prolonged exposure
to chemical compounds leading to drug-induced (di)-long QT syndrome, and
results in an increased susceptibility to cardiac arrhythmias. Using CytoPatch™
2 automated patch-clamp equipment, we performed whole-cell recordings in
HEK293 cells stably expressing human Nav1.5, and measured the late Na
component as average current over the last 100 ms of 300 ms depolarizing
pulses to -10 mV from a holding potential of -100 mV, with a repetition
frequency of 0.33 Hz. Averaged values in different steady-state experimental
conditions were further corrected by the subtraction of current average during
the application of tetrodotoxin (TTX) 30 μM. We show that ranolazine at 10 and
30 μM in 3 min applications reduced the late Na  current to 75.0 ± 2.7% (mean
± SEM,  = 17) and 58.4 ± 3.5% (  = 18) of initial levels, respectively, while a 5n n
min application of veratridine 1 μM resulted in a reversible current increase to
269.1 ± 16.1% (  = 28) of initial values. Using fluctuation analysis, we observedn
that ranolazine 30 μM decreased mean open probability  from 0.6 to 0.38p
without modifying the number of active channels , while veratridine 1 μMn
increased  2.5-fold without changing . In human iPSC-derivedn p
cardiomyocytes, veratridine 1 μM reversibly increased APD90 2.12 ± 0.41-fold
(mean ± SEM,  = 6). This effect is attributable to inactivation removal inn
Nav1.5 channels, since significant inhibitory effects on hERG current were
detected at higher concentrations in hERG-expressing HEK293 cells, with a
28.9 ± 6.0% inhibition (mean ± SD,  = 10) with 50 μM veratridine.   n    
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Introduction
The late cardiac Na+ current can be recorded 10–100 milliseconds 
after membrane depolarization as a sustained inward current com-
ponent (I
sus
) in cardiomyocytes1. This late current represents a frac-
tion of voltage-dependent Na+ channels that fail to inactivate after 
the initial opening. Instead, these channels change to a conformation 
with frequent late re-openings in a so-called burst mode2. Among 
other mechanisms, calmodulin kinase II overexpression in chronic 
heart failure increases the rate of transition to the late bursting 
mode conformation2. The phenomenon is also observed in Na
v
1.5 
inactivation-deficient mutants, such as ΔKPQ3 or 1795InsD4,5, lead-
ing to a specific form of congenital long QT syndrome, LQT-36–8.
Given its role in cardiac arrhythmogenesis9,10, pharmacological 
inhibition of the late Na+ current component (INa late) is seen as an 
anti-arrhythmic strategy. Novel late sodium channel blockers, such 
as the partial fatty acid beta-oxidation inhibitor, ranolazine11–15, are 
used for both myocardial ischemia and to alleviate neuropathic pain 
and show a preferential affinity for the burst mode conformation of 
Na+ channels16–21. Other compounds, such as veratridine, a steroid-
derived alkaloid extracted from rhizomes of Veratrum album or 
seeds of Schoenocaulon officinale22,23, preferentially bind to acti-
vated Na+ channels, impeding inactivation and leading to increased 
nerve excitability.
The objectives of this study were to (1) record the veratridine-
dependent increase in the late Na+ current using a HEK293 cell line 
stably transfected with human Na
v
1.524, (2) measure the ranolazine-
induced inhibition of basal and veratridine-activated INa late, and 
(3) asses the effects of veratridine at the same concentrations on 
action potentials (APs) in hiPSC-cardiomyocyte preparations exter-
nally paced in current-clamp mode. In parallel we also tested the 
inhibitory effects of veratridine on hERG1 current in stably trans-
fected HEK293 cells. All these experiments were performed using 
CytoPatch™2 automated patch-clamp equipment.
Materials and methods
All experiments were performed using the CytoPatch™2, using 
standard dual-channel Cytocentrics chips with embedded quartz 
pipette tips 2 μM in diameter. For whole-cell late Na+ current 
recordings, the voltage-clamp protocol consisted of repeated depo-
larizing pulses of -10 mV amplitude and 300 ms duration, from a 
holding potential of -100 mV, to allow a substantial removal from 
inactivation of Na
v
1.5 channels. The peak and late Na+ current were 
plotted and monitored over the entire duration of experiment, and 
extracted from recorded data for further analysis. Pharmacologi-
cal compounds were applied in a predefined sequence using the 
dispensing needle of automated equipment. All experiments were 
performed at room temperature (21–22°C).
For whole-cell hERG current recordings, cells were held at -70 mV. 
After a brief 100-ms prepulse to -50 mV to determine the current 
leak, a 2-s depolarizing voltage step to +40 mV was followed by a 
2-s step to -50 mV to elicit hERG tail currents every 10 s. Peak tail 
current amplitude was corrected by the leak current and the cor-
rected peak tail current was averaged over the last three pulses of 
the control phase (I
ctrl) and the application phase (Icpd), respectively. 
From these averaged values the hERG tail current inhibition was 
calculated as follows:
Inhibition = 1 – (I
cpd/Ictrl)
iPSC-CM recordings were performed in current-clamp mode, using 
repeated sweeps consisting of 3 injected current pulses of 2000 pA 
amplitude, 0.5 ms duration, at 3-s intervals. During solution uptake 
the system was switched to voltage-clamp mode.
Cell cultures and preparations
HEK293 cells stably expressing either the human Na
v
1.5 channel 
or the hERG K+ channel were used as ready-to-use frozen Instant 
cells (product of Cytocentrics). Cells, kept in liquid nitrogen, were 
quickly thawed, centrifuged, resuspended in extracellular solution at 
a density of ~106 cells/ml, and used for experiments within 3 hours. 
For other experiments, Nav1.5-expressing cells were cultured in 
25 cm2 flasks in DMEM supplemented with 10% fetal bovine serum 
and 100 μg/ml zeozin, and kept at 37°C, 8% CO2 in a humidified 
incubator. Adherent cell monolayers were detached with Versene 
(ethylenediaminotetraacetic acid – EDTA 0.02% in phosphate 
buffered saline - PBS), centrifuged for 2 min at 100 × g, and resus-
pended in hERG external solution.
hiPSC-derived iCell® Cardiomyocytes were kindly provided by 
Cellular Dynamics International (Madison, WI) as frozen samples, 
and cultured in monolayers in 12-well plates coated with 0.1% gel-
atin, for up to 41 days. The thawing/plating and maintenance media 
were provided by the cell supplier. For detachment, the monolay-
ers were rinsed twice with calcium and magnesium-free PBS, then 
incubated for 2 min with trypsin 0.1% at 37°C. 1.5 ml of medium 
was added per well, the cells were suspended, centrifuged at 180 × g 
for 5 min, and resuspended in a 1:1 mixture of culture medium and 
hERG extracellular solution.
Solutions and chemicals
For recordings in Na
v
1.5-transfected HEK293 cells the external 
solution had the following composition (in mM): NaCl 130, CsCl 5, 
CaCl2 2, MgCl2 1.2, HEPES 10, D-glucose 5, pH 7.4, osmolality 
320 mOsm/kg. The internal solution contained (in mM): Cs-aspartate 
70, CsCl 60, CaCl2 1, MgCl2 1, Na2ATP 5, EGTA 11, HEPES 10, 
pH 7.2 with CsOH, osmolality 290 mOsm/kg. For recordings in 
iPSC-derived cardiomyocytes and hERG-transfected HEK293 cells 
the extracellular solution had the following composition (in mM): 
140 NaCl, 2.5 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES, 10 Glucose, 15 
Sucrose. The pH was adjusted to 7.4 with NaOH 1M and the osmo-
lality to 320 (± 5) mOsmol/kg with sucrose 1M, and the storage 
temperature was 4°C. The intracellular solution contained (in mM): 
100 K Gluconate, 20 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 11 EGTA-
KOH, 4 ATP-Mg2+, 3 Phosphocreatine-Na2-H2O, 9 Sucrose. The 
pH was adjusted to 7.2 with KOH 1M, the osmolality to 295 (± 5) 
mOsmol/l, and then it was stored in 10-ml aliquots at -20°C, thawed 
and used within 4 hours. Veratridine (Sigma V5754) working solu-
tions at 1, 5 and 50 μM were prepared from a 50 mM stock solution 
in ethanol. Ranolazine dihydrochloride (Sigma R6152) 10 and 
30 μM was prepared from a 10 mM stock solution in DMSO. TTX 
(BN0518, Biotrend, Zurich, CH) was prepared from a 1 mM aque-
ous stock solution.
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Data storage and analysis
The software files generated during the recordings were stored on 
computer hard disks. Patch clamp data were analyzed using the 
CytoPatchTM software and exported to Microsoft Excel or pClamp10 
(Axon Instruments, part of Molecular Devices, Sunnyvale, CA) 
for further analysis, using a proprietary conversion tool. APD90 
analysis for current-clamp recordings in iPSC-derived cardiomyo-
cytes was performed with self-written software routines. APD90 
was computed as the duration between the point of maximal AP 
upstroke speed during phase 0 to recovery of 90% of the difference 
between peak upstroke potential and resting potential. In the case 
of veratridine application, if recovery was incomplete during the 3-s 
interstimulus interval, APD90 was computed over several pacing 
cycles. For statistical analysis, one-way ANOVA for independent 
samples with Dunnett’s post-hoc comparison, as well as Student’s 
t tests where appropriate, were applied, at a level of significance of 
p ≤ 0.05, using the GraphPad Prism software (La Jolla, CA).
Results
1. Late Nav1.5 sodium current component
Using automated voltage-clamp protocols applied to human Nav1.5-
expressing HEK293 cells in the above mentioned conditions, we 
routinely recorded, in high-quality seal conditions (both seal and 
membrane resistance > 1 GΩ), and with stability for at least 20 min, 
whole-cell Na+ currents. These currents were elicited by membrane 
depolarization to -10 mV from a holding potential of -100 mV, 
required for the proper removal from inactivation of cardiac Na+ 
channels. The late Na+ current component (INa late) was automati-
cally computed and plotted as time average over the last 100 ms of 
the 300-ms depolarizing pulse of each sweep. Figure 1A shows the 
time course of 5 averaged experiments including repeated appli-
cations of veratridine 1 μM with different durations (2 min, 1 min, 
5 min), as well as a 1-min application of TTX 30 μM, resulting 
in the rapid complete block of late Na+ current. The average cur-
rent level during TTX application in each experiment was sub-
sequently subtracted from all other averaged steady-state levels 
to obtain unbiased estimations of INa late in different experimental 
conditions. In general, reversibility was good and rapid upon TTX 
wash-out.
2. Late sodium current activation by veratridine and block by 
ranolazine in Nav1.5 cells
Under control conditions, a 5-min application of veratridine 1 μM 
induced an increase of the late Na+ current by 269.1 ± 16.1% (mean 
± SEM, n = 28) of initial values (Table 1 and Figure 2). Figure 1B 
shows representative current traces of selected sweeps, as well as 
Figure 1. Activation by veratridine of the late Na+ current in Nav1.5-expressing cells. A. Time course of INa late (average transmembrane 
current during the last 100 ms of a 300-ms depolarizing pulse to -10 mV from a holding potential of -100 mV) during a typical experiment with 
repeated applications of veratridine 1 μM and a final application of TTX 30 μM. B. Overlap of individual sweeps showing the peak and late 
component of INa during the application of veratridine 1 μM, the co-application with ranolazine 10 μM, and with TTX 30 μM. The peak and late 
INa component are shown separately in inserts using magnified time and voltage scales, respectively.
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Table 1. Effects of ranolazine 10 and 30 μM and veratridine 1 μM on TTX-sensitive* late Na+ current.
Experiment Absolute values (mean ± SEM)
Relative values 
(mean ± SEM)
Drug application 
(n = number of cells tested)
INa late initial 
(pA)
INa late drug 
(pA)
INa late final 
(pA)
INa late initial 
(%)
INa late drug 
(%)
p value 
vs. initial§
INa late final 
(%)
p value 
vs. initial§
Ranolazine 10 μM 3 min 
(n = 17) -13.2 ± 2.6 -9.7 ± 1.8 -13.2 ± 2.3 100 75.0 ± 2.7 7.8E-8 105.6 ± 5.0 0.280
Ranolazine 30 μM 3 min 
(n = 18) -10.6 ± 2.2 -6.1 ± 1.4 -11.9 ± 2.8 100 58.4 ± 3.5 1.1E-9 107.7 ± 7.7 0.330
Veratridine 1 μM 5 min 
(n = 28) -12.4 ± 1.9 -36.3 ± 6.7 -15.8 ± 2.7 100 269.1 ± 16.1 4.7E-11 114.2 ± 8.2 0.095
* INa late values were computed by subtraction of averaged amplitude in the presence of TTX 30 μM from averaged amplitudes in all other experimental 
conditions
§ using two-tailed Student’s t test for paired samples
Figure 2. Effects of ranolazine, TTX and veratridine on the late Na+ current in Nav1.5-expressing cells. A. Time plots of INa late in four 
typical experiments. Intervals of application of ranolazine 10 or 30 μM, TTX 30 μM, and veratridine 1 μM are indicated. Right panels: INa late 
traces from 260 to 270 ms at the time points marked with arrows and numbered in the left panels. B and C. Effects of ranolazine 10 and 30 μM, 
respectively, on relative levels of TTX-sensitive late Na+ current. D. Effect of veratridine 1 μM. Mean values are indicated for each condition, 
and error bars represent SEM.
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magnified inserts of the peak and late phase, within an individual 
experiment. The application of veratridine 1 μM increased the late 
current amplitude by more than two-fold relative to the TTX 30 μM 
reference trace, without any noticeable effect on peak current, while 
the co-application of ranolazine 10 μM reduced the peak current 
with apparently no effect on the late component. Systematic experi-
ments with ranolazine applied alone demonstrated INa late reduction 
to 75.0 ± 2.7% (mean ± SEM, n = 17) of initial values at 10 μM, and 
58.4 ± 3.5% (mean ± SEM, n = 18) at 30 μM (Table 1 and Figure 2).
Figure 3 shows the power density spectra of Fourier-transformed 
traces recorded under different conditions, as numbered in the 
upper time course of the experiments. Presumably, the opening and 
closure of Nav1.5 channels in the late gating mode conformation 
produces a Lorentzian component with corner frequency above 
2 KHz. However, due to the reduced number of individual signal 
sources, the plateau spectral power density was small and difficult 
to distinguish. A better approach to fluctuation analysis is by the 
computation of single-channel parameters such as the mean open 
probability p and the average number of channels n, starting from 
the well-known estimations of current variance σ 2 and macroscopic 
current I 25:
σ 2 = npi2 – np2i2 = np(1 – p)i2 and I = npi
We used a unitary Na+ current amplitude i at -10 mV of 1.43 pA, 
based on the unitary current amplitude of 2 pA at -40 mV observed 
in single-channel recordings of Nav1.5 late currents in HEK293 
cells26 and a reversal potential of +65 mV. In doing so, we could 
evaluate the mean open probability p and further the average num-
ber of Na+ channels n open in the late mode in selected traces, 
over the last 100 ms of activity during the 300-ms depolarizing 
pulses. It was observed that 30 μM ranolazine application resulted 
in a decrease of mean open probability from 0.6 to 0.38, without 
affecting the average number of channels contributing the late Na+ 
current (n = 4), in agreement with estimates obtained from aver-
aged macroscopic currents. On the other hand, veratridine 1 μM 
increased the number of channels in late gating mode to n = 10, 
without influencing the mean open probability.
3. di-APD prolongation in iPSC-CM by application of 
veratridine
To get a better understanding of the role that the late Na+ current 
may play in arrhythmogenesis and in the complex mechanisms of 
di-LQT syndrome, we performed a series of automated patch-clamp 
Figure 3. The late Na+ current presents fluctuations due to the opening and closure of individual channels. A. Time course of a typical 
experiment in Nav1.5-expressing cells showing the effects of ranolazine 30 μM, TTX 30 μM, and veratridine 1 μM on INa late. B. Averaged Fourier 
transforms of multiple traces recorded in different conditions in the experiment shown in A: 1. initial control; 2. ranolazine 30 μM; 3. TTX 30 
μM; 4. veratridine 1 μM; 5. veratridine 50 μM. C. Fluctuation analysis of individual traces recorded during the five distinct periods shown in A 
allowed the distinction of individual channel gating events and the computation of the average open probability p and the average number 
of channels n for each condition.
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experiments on hiPSC-derived cardiomyocytes with current-clamp 
recordings of stimulus-triggered APs. Each recorded sweep con-
tained responses elicited by three injected current stimuli (0.5 ms 
duration, 2 nA amplitude). As shown in Figure 4, veratridine 1 μM 
induced a marked prolongation of AP duration, reaching saturation 
in less than 3 min. Further application of 5 μM veratridine resulted 
in further APD90 prolongation, exceeding the interstimulus inter-
val. There was a slow trend to reversibility during the wash-out 
phase. Quantitative results for veratridine 1 μM application are 
summarized in Table 2. Thus, in n = 6 experiments at room tem-
perature the relative APD90 prolongation induced by veratridine 
was 2.12 ± 0.41 fold (mean ± SEM), reversible to 1.21 ± 0.50 fold 
at wash-out (mean ± SEM, n = 4).
4. Weak hERG inhibition by veratridine
Last, we performed experiments using HEK293 cells stably express-
ing hERG1 to assess the effects of veratridine at different concen-
trations on this current component, in order to better understand 
the complex effects of this compound on the action potential of 
iPSC-derived cardiomyocytes. As shown in Figure 5, veratridine 
concentrations up to 5 μM did not produce levels of hERG inhi-
bition significantly different than the diluting vehicle alone (etha-
nol 0.1%), while at 50 μM there was a 28.9 ± 6.0% (mean ± SD, 
n = 10) inhibition of peak hERG current, a statistically significant 
effect (p < 0.0001, one-way ANOVA for independent samples with 
Dunnett’s multiple comparison test vs. control).
Dataset 1. Experimental data showing the effect of veratridine, 
ranolazine and TTX on late Na+ currents in cultured cells
http://dx.doi.org/10.5256/f1000research.5544.d36993
Patch-clamp data showing the effects on late Na+ current after 
veratridine, ranolazine and TTX treatment in Nav1.5-expressing 
HEK293 cells, the effect of veratridine on hERG currents and 
on externally paced action potentials in iCell® Cardiomyocytes 
assessed with CytoPatch™2 automated patch-clamp equipment. 
For more details, please see the legend file in Dataset 1.
Figure 4. AP prolongation by veratridine in human iPSC-derived cardiomyocytes. Current-clamp AP recordings using a pacing protocol 
with injected current stimuli of 0.5-ms duration and 2 nA amplitude repeated at 3-s intervals. The overlap of traces in control conditions at 
the start of the experiment, with 1 μM veratridine (onset and full effect), with 5 μM veratridine, and during wash-out, shows partial recovery.
Table 2. Changes in APD90 duration (in ms, mean ± SEM) induced by veratridine in hiPSC-derived 
cardiomyocytes.
Experimental 
condition
APD90 
initial
APD90 
during appl.
APD90 
wash-out
Relative APD90 
during appl.
Relative APD90 
wash-out
Veratridine 1 μM 777.5 ± 179.1 1429.3 ± 289.8 688.0 ± 86.9 2.12 ± 0.41 1.21 ± 0.50
p 0.02482 0.65037
n 6 6 4 6 4
Ethanol 0.1% 
control 893.8 ± 343.8 1013.0 ± 408.4 917.3 ± 318.3 1.08 ± 0.07 1.17 ± 0.17
p 0.16664 0.75986
n 4 4 4 4 4
Relative values are computed taking initial values as reference
p values for Student’s t test for paired samples, two-tailed, for condition tested vs. initial values
n = number of cells included in analysis
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Discussion
The main findings of the present study using the CytoPatchTM2 
instrument are the following: (1) inhibition of cardiac late Na+ cur-
rent to 75.0% and 58.4% of initial values by ranolazine 10 and 30 μM, 
respectively; (2) activation of the same current by veratridine 1 μM 
to 269.1% of initial values; and (3) prolongation of APD90 by vera-
tridine 1 μM to 212% of initial values in human iPSC-derived car-
diomyocytes. We have succeeded in recording and analysing the 
small (a few picoA) late Na+ current component in a human cell line 
stably transfected with wild-type human SCN5A, using automated 
patch-clamp technology, with a voltage protocol different from that 
used in the first electrophysiology characterization of ΔKPQ LQT-3 
mutant Na+ channels3. We observed that instrumental noise does not 
significantly affect the average current value over the last 100 ms 
of a 300-ms depolarizing pulse from -100 to -10 mV, therefore this 
value can be computed and plotted in real-time, representing a 
sensitive indicator for evidencing pharmacological effects in auto-
mated patch-clamp assays. Another critical parameter is the fre-
quency of repetition of depolarizing stimuli, because it may reveal 
use dependency for compounds exerting state-dependent binding 
effects27. Although in the present set of experiments we kept a fixed 
value of 0.33 Hz, inclusion of different pacing rates in future vari-
ants of the assay may offer supplementary information of pharmaco-
logical relevance. An important tool in the precise assessment of INa 
late levels is the application of TTX 30 μM, which results in an almost 
complete late Na+ current inhibition, and offers a current reference 
used for the correction by subtraction of all other values in different 
experimental conditions. An excellent seal stability and access resist-
ance, such as those offered by the Cytocentrics microfluidic chips28, is 
another prerequisite for successful late Na+ pharmacology experiments.
Due to the limited amplitude of late Na+ current under basal con-
ditions, we increased it using low concentrations of veratridine, 
a steroid-derived natural alkaloid known to bind to an intramem-
brane site of Na+ channel pore subunits and, in doing so, stabilize 
it in the open conformation29,30, contributing to the INa late. Although 
veratridine at 1 μM resulted in a consistent 2.5 – 3-fold increase in 
late Na+ current, compared to initial levels (Table 1 and Figure 1– 
Figure 3), we would not recommend this procedure for pharmacol-
ogy assays because of possible interactions between veratridine and 
test compounds. Although we have not systematically explored this 
phenomenon, preliminary observations, as shown in Figure 1B, sug-
gest a reduced effectiveness of ranolazine 10 μM when co-applied 
with veratridine, compared to application of ranolazine alone at 
the same concentration. The value of relative inhibition of the late 
Na+ current by ranolazine 10 μM in the single compound applica-
tion obtained in our study (75.0% of control levels) is larger than 
those obtained with the same concentration of ranolazine on late 
Na+ current activated by veratridine 40 μM (89% and 81% for hold-
ing potentials of -110 mV and -90 mV, respectively)31. An elegant 
method that may offer pharmacologically relevant information con-
cerning the site and mechanism of action of a certain compound is 
fluctuation analysis. As shown in Figure 3, when applied to selected 
traces, this method allows the computation of the mean open prob-
ability p and the average number of open channels n contributing to 
current variance. From this analysis, we hypothesize that ranolazine 
acts as an open pore blocker, reducing the mean open probability at 
30 μM to 63% of initial values, from 0.6 to 0.38, without lowering 
the number of active channels, while veratridine 1 μM increases 
the number of active channels in late gating mode 2.5-fold, without 
influencing their mean open probability.
Figure 5. Effects of veratridine on hERG channels. A. Current traces in control conditions (upper) and during application of veratridine 
50 μM (lower trace). B. Percentages of peak hERG current inhibition by different concentrations of veratridine and control ethanol 0.1% 
vehicle. Error bars represent SD. Number of experiments: control (n = 6), veratridine 0.1 μM (n = 10), 1 μM (n = 5), 5 μM (n = 7), 50 μM (n = 10).
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hERG: human ether-á-go-go related gene
SEM: standard error of the means
SD: standard deviation
DMEM: Dulbecco’s modified Eagle’s medium
DMSO: dimethylsulfoxide
HEPES: N-2-hydroxyethylpiperazine-N´-2-ethansulfonic acid
EGTA: ethylene glycol-bis(ß-aminoethyl ether)-N,N,N,N´-tetraacetic 
acid
ATP: adenosine triphosphate
TTX: tetrodotoxin
IC: intracellular solution (pipette-filling solution)
EC: extracellular solution
PBS: phosphate-buffered saline
iPSC-CM: induced pluripotent stem cell-derived cardiomyocytes
APD: action potential duration
Author contributions
HA and TK conceived the study. OS and BA designed the experi-
ments. MC, BA, VG and OS carried out the research. OS and BA 
prepared the first draft of the manuscript. HT and HA contributed 
to the experimental design and preparation of the manuscript. All 
authors were involved in the revision of the draft manuscript and 
have agreed to the final content.
Competing interests
None of the authors has competing interests concerning the present 
study, except for the participation of TK, OS and BA in the Cyto-
centrics company.
Grant information
This study was in part funded by a BMBF grant 03WKCC4D, 
TransCure NCCR Network to HA, and Austrian Science Fund FWF 
(grant W1232-B11).
The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
Acknowledgements
The authors gratefully acknowledge Stefanie Frech, Jörg Eisfeld, 
Ingrid Rosenkranz, Juliane Böttcher, Christian Scherpeltz, Yassine 
M. Amarcouch and Jean-Sébastien Rougier for their support, 
and Cellular Dynamics International for the provision of iCell® 
Cardiomyocytes.
In agreement with the significant activatory effects of veratridine 
1 μM on cardiac Nav1.5 channels in late gating mode in stably 
transfected cell lines, we found an important prolongation of action 
potential duration when the drug was applied to human iPSC-
derived cardiomyocytes in current-clamp configuration, using 
CytoPatch™2 automated patch-clamp equipment. The APD90 was 
increased over twofold by veratridine 1 μM, with a good revers-
ibility upon wash-out (Table 2), and an even higher prolongation 
with 5 μM (Figure 4), although in this case we were unable to accu-
rately compute APD90 values for externally paced APs, due to their 
overlap with the next stimulus. This effect is consistent with the 
findings of previous studies, showing APD prolongation in bron-
chial smooth muscle cells upon veratridine application32, and the 
enhancement of AP burst generation by veratridine in rat trigeminal 
sensory neurons33. Furthermore, we have demonstrated that hERG 
inhibition does not play any role in the observed APD prolonga-
tion by veratridine at 1 or 5 μM, since significant hERG inhibition 
occurred with higher veratridine concentrations (Figure 5). A recent 
combined in vivo and in vitro study proved that the augmentation 
of the myocardial late Na+ current during ventricular remodeling 
induced by pulmonary arterial hypertension in rats was accom-
panied by significant APD90 increases, and a beneficial effect of 
repeated ranolazine administration via late Na+ current block was 
demonstrated with a subsequent alleviation of induced intracellular 
Ca2+ overload34.
In conclusion, the present study demonstrates that automated patch-
clamp, as implemented by the CytoPatch™2 equipment using our 
proprietary CYTOCENTERING technology and quartz pipette 
tips embedded in silicon microfluidic chips28,35, which allow high-
quality stable seals, lead to reliable late Na+ current pharmacology 
recordings, with results at least comparable to those obtained in 
manual patch-clamp experiments. In addition, automation may 
prove advantageous given the small amplitude of late Na+ current, 
which therefore requires a large number of experiments for the 
accurate assessment of pharmacological effects.
Data availability
F1000Research: Dataset 1. Experimental data showing the effect 
of veratridine, ranolazine and TTX on late Na+ currents in cultured 
cells, 10.5256/f1000research.5544.d3699336
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QC, Canada
In this study, Chevalier  had succeeded to record and analyse the late Na  current (I ) in HEK293et al.
cells stably transfected with wild-type human SCN5A, using automated patch-clamp technology. They
were able to accurately assess the effects of pharmacological agents on I . They showed that the
cardiac I  can be inhibited by ranolazine and activated by veratridine. Using fluctuation analysis, they
hypothesized that ranolazine would act as an open pore blocker, reducing the open probability without
affecting the number of active channels, while veratridine would increase the number of active channels
without influencing their open probability. In addition, they also provided additional functional data by
performing a series of automated patch-clamp experiments showing that application of veratridine
concentrations that increased I  but had no effects on HERG current prolonged the action potential
duration of human iPSC-derived cardiomyocytes.
 
This is an interesting and well-designed study that reports high quality data. Considering the role of late
sodium current in the action potential duration, mainly under pathological conditions, and the difficulty to
accurately record this small ionic current, the subject of this study is highly relevant. The demonstration of
the suitability of the automated patch clamp technology to accurately measure the late sodium current and
to assess the effects of pharmacological agents on this current is helpful. In addition, the use of the hiPSC
–derived cardiomyoyctes with this approach is also interesting. I do not have any major issues to address.
However, the paper could be improved by attention to the following points.
 
 All experiments were performed at room temperature. Considering the limited amplitude of the late
Na  current under basal conditions, it could have been useful to perform these experiments at a
more physiological temperature to help increase the amplitude of the current.
 
In Figure 1B, it would have been interesting to also present the recordings with ranolaxine alone.
 
The was elicited by the of 2 nA of . This is a rather large currentaction potential injection current
and is probably not just-suprathreshold depolarizing . Do the hiPSC-derivedcurrent
cardiomyocytes usually require such a high current injection to elicit action potential?
 
For the HERG recordings, is there any specific reason why the external concentration of KCl was
only 2.5 mM?
 
Data reported in Table 1 could have been normalized to the cell capacitance to report the current
+
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Data reported in Table 1 could have been normalized to the cell capacitance to report the current
density instead of the current amplitude.
 
For some statistical analysis, an ANOVA would have been more appropriate that a Student’s testst 
as several groups were examined (eg., Tables 1 and 2).
 
There are few typographic errors in the Abstract: the units for the drugs ranolaxine, veratridine and
TTX are all in millimolar concentrations but should be in the micromolar concentrations.
Overall, the study is interesting and describes a methodological approach that could help study the late
sodium current. The experiments were well designed and presented and the subject of this manuscript is
of importance to the field.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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The paper by Chevalier . analyzed whether late sodium current (I ) can be assessed using anet al
automated patch-clamp device. To this end, the I  effects of ranolazine (a well known I  inhibitor) and
veratridine (an I  activator) were described. The authors tested the CytoPatch automated patch-clamp
equipment and performed whole-cell recordings in HEK293 cells stably transfected with human Nav1.5.
Furthermore, they also tested the electrophysiological properties of human induced pluripotent stem
cell-derived cardiomyocytes (hiPS) provided by Cellular Dynamics International. The title and abstract are
appropriate for the content of the text. Furthermore, the article is well constructed, the experiments were
well conducted, and analysis was well performed.
I  is a small current component generated by a fraction of Nav1.5 channels that instead to entering in
the inactivated state, rapidly reopened in a burst mode. I  critically determines action potential duration
(APD), in such a way that both acquired (myocardial ischemia and heart failure among others) or inherited
(long QT type 3) diseases that augmented the I  magnitude also increase the susceptibility to cardiac
arrhythmias. Therefore, I  has been recognized as an important target for the development of drugs
with either antiischemic or antiarrhythmic effects. Unfortunately, accurate measurement of I  is a time
consuming and technical challenge because of its extra-small density. The automated patch clamp
device tested by Chevalier  resolves this problem and allows fast and reliable I  measurements.et al.
The results here presented merit some comments and arise some unresolved questions. First, in some
experiments (such is the case in experiments B and D in Figure 2) current recordings obtained before the
ranolazine perfusion seem to be quite unstable. Indeed, the amplitude progressively increased to a
maximum value that was considered as the control value (highlighted with arrows). Can this problem be
overcome? Is this a consequence of a slow intracellular dialysis? Is it a consequence of a time-dependent
shift of the voltage dependence of activation/inactivation? Second, as shown in Figure 2, intensity of drug
effects seems to be quite variable. In fact, experiments A, B, C, and D in Figure 2 and panel 2D,
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shift of the voltage dependence of activation/inactivation? Second, as shown in Figure 2, intensity of drug
effects seems to be quite variable. In fact, experiments A, B, C, and D in Figure 2 and panel 2D,
demonstrated that veratridine augmentation ranged from 0-400%. Even assuming the normal biological
variability, we wonder as to whether this broad range of effect intensities can be justified by changes in
the perfusion system. Has been the automated dispensing system tested? If not, we suggest testing the
effects of several K  concentrations on inward rectifier currents generated by Kir2.1 channels (I ).
The authors demonstrated that the recording quality was so high that the automated device allows to the
differentiation between noise and current, even when measuring currents of less than 5 pA of amplitude.
In order to make more precise mechanistic assumptions, the authors performed an elegant estimation of
current variance (σ ) and macroscopic current (I) following the procedure described more than 30 years
ago by Van Driessche and Lindemann . By means of this method, Chevalier et al. concluded that
ranolazine acts as an open pore blocker reducing the open channel probability, while veratridine
increases the number of channels in the burst mode. We respectfully would like to stress that these
considerations must be put in context from a pharmacological point of view. We do not doubt that
ranolazine acts as an open channel blocker, what it seems clear however, is that its onset block kinetics
has to be “ultra” slow, otherwise ranolazine would decrease peak I  even at low frequencies of
stimulation. This comment points towards the fact that for a precise mechanistic study of ionic current
modifying drugs it is mandatory to analyze drug effects with much more complicated pulse protocols.
Questions thus are: does this automated equipment allow to the analysis of the frequency-, time-, and
voltage-dependent effects of drugs? Can versatile and complicated pulse protocols be applied? Does it
allow to a good voltage control even when generated currents are big and fast? If this is not possible, and
by means of its extraordinary discrimination between current and noise, this automated patch-clamp
equipment will only be helpful for rapid I -modifying drug screening. Obviously it will also be perfect to
test HERG blocking drug effects as demanded by the regulatory authorities.
Finally, as cardiac electrophysiologists, we would like to stress that it seems that our dream of testing
drug effects on human ventricular myocytes seems to come true. Indeed, human atrial myocytes are
technically, ethically and logistically difficult to get, but human ventricular are almost impossible to be
obtained unless from the explanted hearts from patients at the end stage of cardiac diseases. Here the
authors demonstrated that ventricular myocytes derived from hiPS generate beautiful action potentials
that can be recorded with this automated equipment. The traces shown suggested that there was not
alternation in the action potential duration. Is this a consistent finding? How long do last these stable
recordings? The only comment is that resting membrane potential seems to be somewhat variable. Can
this be resolved? Is it an unexpected veratridine effect? Standardization of maturation methods of
ventricular myocytes derived from hiPS will be a big achievement for cardiac cellular electrophysiology
which was obliged for years to the imprecise extrapolation of data obtained from a combination of several
species none of which was representative of human electrophysiology. The big deal will be the maturation
of human atrial myocytes derived from hiPS that fulfil the known characteristics of human atrial cells.
Minor points:
We suggest suppressing the initial sentence of section 3. We surmise that results obtained from the
experiments described in this section cannot serve to understand the role of I in arrhythmogenesis.
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